Back

Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.

Sovateltide

PipelinePhase 3PeptideInvestigational

Sponsor:: Pharmazz, Inc.
Active US trials:: 1
Earliest primary completion:: Sep 1, 2027

👋

No perspectives yet — be the first!

100% anonymous · Verified U.S. prescribers only

(no name, NPI, or practice ever shown)

Clinical trials (1)

NCT	Phase	Status	Sponsor	Primary Completion
NCT05691244	Phase 3	RECRUITING	Pharmazz, Inc.	Sep 1, 2027

About this drug

Status

Active in clinical trials

Last Refreshed

Physician Buzz

Pre-Approval Insights

Be the First to Share Your Perspective

Share your pre-launch perspective on Sovateltide and help peers make informed prescribing decisions.

Your 45-second perspective helps thousands of colleagues.

Help Peers Make Better Decisions

Your real-world insights guide colleagues

Anonymous to Pharmaceutical Companies

Your identity stays private — only specialty/region shown

See Peer Benchmarks

Compare your perspective to specialty peers

Synopsis

Generated with AlphaAI

Product:

Sovateltide

Category:

Indication:

Mechanism:

Safety:

Dosing:

Patient:

Reviews:

No reviews yet

Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.